Webuildwhat'snext,
bringingimpactthatlasts.
Where patient-driven insight
becomes precision-designed ADCs
We were founded on a simple but powerful idea: to bridge the gap between deep patient insights
and the creation of transformative therapies. Our proprietary P-ADC™ platform, based on our
patient-derived validation engine, allows us to systematically discover and develop therapeutics
that address the most pressing unmet needs in oncology.
Our Technology
P-ADC™
Precision-driven
AimedBio's Platform for Definitive Cure
AimedBio's Platform for Definitive Cure
-
01Needs-based Target DiscoveryIdentification of novel, high-impact targets through in-depth analysis of patient-derived data
-
02Patient-Derived Validation EngineRigorous validation and optimal candidate selection using our proprietary engine of patient-derived models
-
03Modular Open Innovation PlatformRapid and flexible development through strategic open innovation
Our Difference
-
01Patient-Derived Model-
Based P-ADC™ PlatformUtilizing a proprietary P-ADC™ platform and
extensive patient-derived models to
ensure high clinical translatability -
02An Asset-Centric
Value StrategyFocusing on developing a portfolio of
high-value therapeutics to create significant,
long-term asset value -
03A Pipeline of High-Impact
CandidatesTargeting critical unmet needs in oncology
with a portfolio of potential First-in-Class
and Best-in-Class ADC therapies -
04A Partner of Choice for
Industry LeadersChosen by global biopharmaceutical
companies for our asset-centric strategy
and differentiated science
